Table 2 Completed phase I and phase II trials of therapies targeting Notch pathway
Drug | Target | ClinicalTrials.gov identifier | n | Delivery | Disease site | Monotherapy or combination | CR (%) | PR (%) | SD (%) |
|---|---|---|---|---|---|---|---|---|---|
MK-0752 | γ-secretase | NCT00106145 [120] | 103 | Oral | Solid tumors | Monotherapy | 1 (1) | 0 (0) | 10 (10) |
MK-0752 | γ-secretase | NCT00645333 [121] | 30 | Oral | Breast cancer | Combination with docetaxel | 0 (0) | 11 (42) | 9 (34) |
MK-0752 | γ-secretase | NCT00572182 [126] | 23 | Oral | Refractory Pediatric CNS cancer | Monotherapy | 0 (0) | 0 (0) | 2 (9) |
RO4929097 | γ-secretase | NCT01198184 [127] | 17 | Oral | Solid tumors | Combination with temsirolimus | 0 (0) | 0 (0) | 11 (73) |
RO4929097 | γ-secretase | NCT01145456 [119] | 18 | Oral | Solid tumors | Combination with gemcitabine | 0 (0) | 1 (6) | 4 (22) |
RO4929097 | γ-secretase | NCT01131234 [128] | 20 | Oral | Solid Tumors | Combination with cediranib | 0 (0) | 1 (5) | 11 (55) |
RO4929097 | γ-secretase | NCT01116687 [129] | 33 | Oral | Metastatic colorectal cancer | Monotherapy | 0 (0) | 0 (0) | 6 (18) |
RO4929097 | γ-secretase | NCT01232829 [130] | 12 | Oral | Refractory pancreatic cancer | Monotherapy | 0 (0) | 0 (0) | 3 (25) |